![Page 1: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/1.jpg)
Pharmacogenomics
Case study 1: Warfarin
![Page 2: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/2.jpg)
Warfarin overview
Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase.
Warfarin is used to reduce blood clots and after stroke. The therapeutic index (=LD50/ED50) for warfarin is small.
![Page 3: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/3.jpg)
Warfarin is a coumarin, a derviative of dicoumarol, which was discovered in spoiled sweet clover.
It was developed by the University of Wisconsin. The name is derived from Wisconsin Alumni Research
Foundation coumarin. Similar drugs are acenocoumarol and phenprocoumon.
![Page 4: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/4.jpg)
Warfarin action is affected by both pharmacodynamics and pharmacokinetics
Variations in Vitamin K epoxide reductase could result in more or less inhibition by warfarin.
Variations in vitamin K dependent carboxylase could also affect warfarin activity.
Variability in CYP450 2C9 and 3A4 will affect metabolism.
![Page 5: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/5.jpg)
The Vitamin K cycle
![Page 6: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/6.jpg)
Vitamin K is required for formation of γ-carboxyGlu
A number of proteins are known to contain γ-carboxyGlu residues.
These include blood coagulation factors II (prothrombin), VII, IX, and X, the anticoagulant proteins C and S, and the Factor X-targeting protein Z.
This modification is necessary for blood clotting. γ-CarboxyGlu is made in a post-translational modification
requiring vitamin K.
![Page 7: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/7.jpg)
Vitamin Ks are naphthoquinones
![Page 8: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/8.jpg)
The proposed mechanism of vitamin K dependent carboxylase
![Page 9: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/9.jpg)
Does Vitamin K dependent Glu carboxylase affect warfarin response ?
A number of polymorphisms of GGCX have been identified. Most of these are in the non-coding regions. One mutation, R325Q, is found in the coding region. R325Q has about 30% higher activity than “wild-type”. These mutations were found to have only a modest effect (6-
10%) on the warfarin dose. No crystal structure of this endoplasmic reticulum associated
protein has been obtained.
![Page 10: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/10.jpg)
Question?
Vitamin K dependent Glu carboxylase is not the target of warfarin. Why could it affect warfarin activity?
![Page 11: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/11.jpg)
Recycling of vitamin K
After carboxylation, vitamin K is in the oxidized epoxide form.
It needs to be reduced back to the hydroquinone for the next cycle of carboxylation.
This is done by vitamin K 2,3-epoxide reductase. This enzyme is the target of warfarin inhibition.
![Page 12: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/12.jpg)
A bacterial analogue structure of vitamin K reductase
![Page 13: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/13.jpg)
The quinone binding site
![Page 14: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/14.jpg)
The proposed reduction sequence
![Page 15: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/15.jpg)
A possible mechanism for vitamin K epoxide reduction
![Page 16: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/16.jpg)
Polymorphisms in VKOR
Polymorphism Daily Warfarin Dose mg
Resistance Phenotype
Wild type 4–6
A41S 16 Moderate
R58G 34 Major
V66M 31 Major
L28R >45 Severe
V45A Target INR never
Reached
Severe
Common SNPs in
noncoding regions
1–15 Variations across the
“normal” dosing range
![Page 17: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/17.jpg)
Many of these mutations are at or near the quinone binding site
![Page 18: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/18.jpg)
Location of mutations known to affect warfarin binding
![Page 19: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/19.jpg)
Stereochemistry of warfarin inhibition of VKOR
The activity of the two enantiomers towards VKOR differs, with S-warfarin being 3–5 times more potent than R-warfarin.
Warfarin is a racemic mixture. Thus, S-Warfarin accounts for approximately 70% of
the overall anticoagulant activity.
![Page 20: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/20.jpg)
Warfarin resistance has also appeared in animals
Warfarin has been used as rodent poison for about 50 years.
However, resistance has developed in rats and mice. These rodents show polymorphism in VKOR. Resistance may be due at least in part to VKOR
polymorphisms.
![Page 21: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/21.jpg)
Mouse polymorphisms in VKOR
Geographic
area
Amino acid
substitutionsNo. of samples
Berlin E37G 12
Lower Saxony E37G 1
Westphalia R58G 13
R12W, A26S, A48T, R58G, R61L 7
R12W, A26S, A48T, R61L 2
Rhineland L128S 17
Y139C 1
AzoresY139C 1
![Page 22: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/22.jpg)
How do the mutations in rats and mice compare with humans?
Most of the the mutations in rats and mice are different than those is humans.
However, the mutations occur in the same regions of the protein, positions 29 to 48 in exon 1, positions 58 to 67 in exon 2, and 120 to 143 in exon 3.
It is unclear if the mutations in VKOR are solely responsible for resistance in rodents.
Most of the mutations result in reduced enzyme activity.
![Page 23: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/23.jpg)
Question?
Why do all of the mutations found in VKOR result in weaker rather than stronger warfarin binding?
What other enzyme(s) could contribute to warfarin resistance?
![Page 24: Pharmacogenomics Case study 1: Warfarin. Warfarin overview Warfarin is an anticoagulant drug which inhibits vitamin K 2,3-epoxide reductase. Warfarin](https://reader030.vdocuments.us/reader030/viewer/2022033016/56649de35503460f94ad9f42/html5/thumbnails/24.jpg)
Question?
What are some other drugs that should not be used with warfarin?